New immunology data shows INO-3107 induced an expansion of new clonal T cells in blood that were not detectable prior to treatment New clonal T cells in the blood travelled to papilloma and airway tissues and generated an inflammatory and anti-viral response consistent with a reduced need for surgeries for patients with recurrent respiratory papillomatosis (RRP) caused by HPV-6 and HPV-11 Data supporting mechanism of action for INO-3107 to be presented at 36th International Papillomavirus Conference in Ed ...

PLYMOUTH MEETING, Pa., Nov. 6, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that third quarter 2024 financial results will be released after the market close on November 14, 2024. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general ...

American Association for Cancer Research (AACR) Special Conference: Tumor Immunology and Immunotherapy: New immunology data showed ability of INO-3107 to induce an antigen-specific T cell response against HPV-6 and HPV-11 and drive recruitment of T cells into airway tissues and papillomaInternational Society of Vaccines Conference: Full safety and efficacy data from Phase 1/2 clinical study in patients with Recurrent Respiratory Papillomatosis (RRP) indicated that INO-3107 was well tolerated and immunogenic ...

文章核心观点 - Inovio Pharmaceuticals (INO)股价在上一个交易日上涨6.8%,收于5.69美元 [1] - 这一涨幅源于投资者对公司正在开发的针对HPV相关疾病、免疫肿瘤和传染病的DNA药物候选物的潜力持乐观态度 [1] - 公司的领头候选药物INO-3107正处于晚期临床开发阶段,用于治疗复发性呼吸道乳头状瘤 [1] 财务表现 - 公司预计在即将发布的季度报告中将录得每股亏损1.20美元,同比下降11.1% [1] - 收入预计为0.1百万美元,同比下降74.4% [1] 行业动态 - 对于Inovio这样的公司,股价的近期走势往往与盈利预测修订趋势密切相关 [2] - 目前Inovio的季度EPS预测在过去30天内保持不变,这可能意味着短期内股价难以持续上涨 [2] - Inovio所属的医疗-生物医药和遗传学行业中,另一家公司Insmed (INSM)在上一个交易日上涨1.2%,过去一个月下跌1.8% [2][3]

PLYMOUTH MEETING, Pa., Oct. 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conferences: AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy Poster by Dr. Matthew Morrow, VP of Translational Sciences at INOVIO Abstract Title: Reduction in Surgical In ...

PLYMOUTH MEETING, Pa., Sept. 17, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conference: World Congress of Electroporation Oral Presentation by Trevor Smith, VP of Preclinical R&D at INOVIO Abstract Title: Development of in vivo-launched synthetic DNA-encoded antibodies emplo ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of Investor Relations Jacqueline Shea - President & Chief Executive Officer Steve Egge - Chief Commercial Officer Michael Sumner - Chief Medical Officer Peter Kies - Chief Financial Officer Conference Call Participants Anish Nikhanj - RBC Capital Markets Roy Buchanan - Citizens JMP Jay Olson - Oppenheimer Sudan Loganathan - Stephens Yi Chen - H.C. Wainwright Operato ...

财务状况 - 公司现金及现金等价物为3,439.24万美元，较上年同期减少[1] - 公司短期投资为7,602.91万美元，较上年同期减少[1] - 公司预计现金储备可维持至2025年第三季度[11] - 公司通过股票发行筹集了3320万美元的净资金,以加强资产负债表[8] 经营情况 - 第二季度研发费用为2,309.10万美元,较上年同期略有下降[9] - 第二季度总运营费用为3,330万美元,较上年同期下降[9] - 公司研发费用为2,309.10万美元，较上年同期减少[2] - 公司一般及行政费用为1,020.67万美元，较上年同期减少[2] - 公司利息收入为130.74万美元，较上年同期减少[2] - 公司投资联营公司的亏损为33.43万美元[2] - 公司可供出售权益证券的未实现亏损为2.08万美元[2] - 公司净亏损为3,223.71万美元，较上年同期减少[2] - 公司每股基本及稀释亏损为1.19美元，较上年同期减少[2] - 公司加权平均股数为2,719.78万股，较上年同期增加[2] 产品管线进展 - 公司正在推进INO-3107的生物制药许可申请(BLA)准备工作,但由于制造单次使用一次性给药装置组件出现问题,预计将延迟至2025年中期提交BLA[3] - 公司已获得INO-3107在英国的创新药物认证,以及欧洲药品管理局高级治疗药物产品(ATMP)认证[5] - 公司提交了INO-3112用于治疗口咽鳞状细胞癌(OPSCC)的III期临床试验方案,并获得FDA的积极反馈[6] - 公司计划在第三季度向FDA重新提交INO-4201作为Ebola疫苗的异源性增强剂的II/III期临床试验方案[7] - 公司任命Steve Egge为首席商务官,负责INO-3107的商业化策略和运营[8]

PLYMOUTH MEETING, Pa., Aug. 8, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the second quarter of 2024 and provided an update on recent company developments. "We continue to make progress with our lead candidate, INO-3107, which has the potential to significantly improve the lives of patients with R ...

临床试验进展 - 公司正在开发INO-3107用于治疗复发性呼吸道乳头状瘤(RRP)，81.3%的患者在治疗后一年内手术次数减少[89] - INO-3107在临床试验中产生了强大的免疫反应，激活了CD4和CD8 T细胞[89] - 公司计划在2025年中期提交INO-3107的生物制品许可申请(BLA)[89] - 公司正在开发INO-3112用于治疗HPV16/18阳性的口咽鳞状细胞癌(OPSCC)[89] - 公司正在开发INO-5401用于治疗恶性胶质瘤(GBM)[89] 财务状况 - 公司2024年上半年的总收入为10.1万美元[92] - 公司2024年上半年的研发费用为2309.1万美元[92] - 公司2023年6月30日的累计亏损为17亿美元[90] - 公司预计未来将继续产生大额的经营亏损[90] - 公司预计现金储备可维持至2025年第三季度[101] - 2024年4月完成了3.32亿美元的增发[100] 费用分析 - 研发费用同比下降的主要原因包括:停止INO4800项目导致相关制药和临床试验费用减少7.4百万美元[95]、员工和顾问薪酬(含股票激励)减少7.2百万美元[95]、停止其他COVID-19研究相关的制药和工程服务费用减少3.2百万美元[95]、其他项目的制药费用减少4.7百万美元[95][1] - 一般及行政费用同比下降,主要是员工薪酬(含股票激励)减少3.9百万美元[96]、法律费用减少2.3百万美元[96][2] - 股票激励费用同比下降,主要是2024年授予的股票平均授予日公允价值较低[96][3] - 利息收入同比下降,主要是短期投资余额减少[96][4] - 利息费用同比下降,主要是可转换票据已于2024年3月全额偿还[96][5] - 投资联营公司公允价值变动损失为460,000美元[96][6] - 可供出售股权证券公允价值变动收益为480,000美元[96][7]